Equity
€107,778 from €197,070 in 2018
Equity fell by 45% in 7 years.
DM BIOMED DEVELOPMENT
Lifetime
14 annual accounts with figures on one time axispeak €73,213 (2013)
€45,196▲ 59.7%
lowest -€11,981 (2023)
€30,532▲ 46.2%
peak €197,070 (2018)
€107,778▲ 39.5%
€16,855▲ 332%
Board1 name since 2012
1 directorMARÉCHAL Daniel Jean Henri Ghislain
Documentsfilings and deeds
24-02-202665 days before the deadline
2025micro format
Gross margin from €28,293 to €45,196Result from €20,879 to €30,532Equity from €77,246 to €107,778Debts from €3,899 to €16,855Investments €3,587Cash from €51,447 to €83,994
Key points
from the 2025 annual accountsTurnover
≈ €130,000 estimated
The micro format states no turnover.
Investments
€3,587 8.0 × depreciation
Green is investment, beige is depreciation.
Liquidity
7.21 was 20.71 in 2024
Short-term debts rose from €3,899 to €16,805.
Filings
14 annual accounts since 2012
The last five annual accounts were filed 5 to 71 days before the end of the period.
Position in the sector
86.5%
Higher solvency than 84% of companies in head offices and management consultancy. Sector median 55.5% · 39,364 companies.
Checked score
98
Excellent
Financially stronger than 81% of micro companies in head offices and management consultancy (NACE 70)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 48,570 companies (NACE 70, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025highest value
05-2025: < 0.1%▼ -0.1 percentage points vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
lowers risk
Liquidity: current ratio 7.21, cash €83,994
Equity €107,778 (86.5% of total assets)
Sector: Activities of head offices; management consultancy activities (NACE 70)
Size: total assets €124,632
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro). It does better than 86% of them on solvency, 92% on liquidity, 68% on profitability and 77% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-09-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 34,693 companies had the same profile as DM BIOMED DEVELOPMENT has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
That fits the bankruptcy probability of DM BIOMED DEVELOPMENT itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for DM BIOMED DEVELOPMENT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €10,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 7.21 (20.71 in 2024), above the usual 1.5. Short-term debt is 13.5% and cash 67.4% of total assets. 13.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
6 signals, none raises the risk
Six signals.
lowers riskneutral
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
19202122232425
2019 to 2025 · latest year €107,778
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 24-02-2026, 65 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
65 days early
2024
5 days early
2023
71 days early
2022
25 days early
2021
51 days early
2020
81 days early
2019
77 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 54 days before the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 10 March (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-09-2026 year end10-11-2026 today30-04-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0842657707
Reappointment: MARÉCHAL Daniel Jean Henri Ghislain (director)
General meeting of 29-06-2023 · Gazette deed
Incorporation
published on 16-01-2012 · Gazette deed
First establishment
Rue des Montys 53, Sprimont
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DM BIOMED DEVELOPMENT Sprimont | €124,632 | €45,196 | 86.5% | - |
| BISANGA Chaudfontaine | €129,147 | €42,549 | 52.6% | - |
| TODA SPRL Awans | €112,720 | €45,317 | 37.8% | - |
| RY CONSULTANCY MANAGEMENT AND DEVELOPMENT Liège | €105,747 | €42,740 | 66.5% | - |
| TP SQUARE CONSULTING Dison | €142,316 | €39,854 | 64.4% | - |
| JPS Business Consulting Waimes | €134,466 | €37,517 | 81.6% | 0.6 |
| OH SERVICES Woluwe-Saint-Pierre | €123,969 | €43,874 | 67.5% | 0.1 |
These companies have the same main activity as DM BIOMED DEVELOPMENT: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €106,000 and €142,000, founded between 2010 and 2012.
Official details
Source: KBO- Status
- Active since 12-01-2012Normal situation
- Activity
- Business and other management consultancyNACE 70200
- Establishment unit
- 2.206.672.8934141 Sprimont, since 12-01-2012
- Financial year end
- 30 September
- Peppol
- Reachable since 15-09-2025
Annual accounts to 30-09-2025
- €124,632▲ 53.6%
- Filing
- Filed on 24-02-2026, 65 days before the end of the filing period
Insights on DM BIOMED DEVELOPMENT
DM BIOMED DEVELOPMENT files the micro format. That format states no turnover. The gross margin fell from €67,517 in 2012 to €45,196 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DM BIOMED DEVELOPMENT
- What is the company number of DM BIOMED DEVELOPMENT?
- The company number of DM BIOMED DEVELOPMENT is 0842.657.707. The VAT number is the same number with BE in front: BE 0842.657.707.
- Where is DM BIOMED DEVELOPMENT based?
- The registered office is at Rue des Montys 53, 4141 Sprimont.Company details
- What does DM BIOMED DEVELOPMENT do?
- According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
- What is the legal form of DM BIOMED DEVELOPMENT?
- DM BIOMED DEVELOPMENT is a private limited company (BV).
- When was DM BIOMED DEVELOPMENT founded?
- DM BIOMED DEVELOPMENT was founded on 12-01-2012.
- Is DM BIOMED DEVELOPMENT still active?
- Yes, DM BIOMED DEVELOPMENT is an active enterprise in the KBO register.
- What is the turnover of DM BIOMED DEVELOPMENT?
- The turnover in financial year 2025 is ≈ €130,000. This figure is estimated from the gross margin of €45,196 and 144 comparable companies (NACE 70200). It probably lies between €79,000 and €180,000.Financials
- Is DM BIOMED DEVELOPMENT profitable?
- In financial year 2025, DM BIOMED DEVELOPMENT made a profit of €30,532.
- Where can I find the annual accounts of DM BIOMED DEVELOPMENT?
- DM BIOMED DEVELOPMENT filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DM BIOMED DEVELOPMENT due?
- DM BIOMED DEVELOPMENT must file the annual accounts for financial year 2026 by 30-04-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.